Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) from a sell rating to a hold rating in a research report report published on Friday.
According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “
Separately, HC Wainwright restated a buy rating and issued a $12.00 price objective on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Tuesday, August 21st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $10.94.
Institutional investors and hedge funds have recently bought and sold shares of the business. MYDA Advisors LLC acquired a new stake in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter valued at about $195,000. Platinum Investment Management Ltd. acquired a new stake in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter valued at about $2,532,000. Finally, Temasek Holdings Private Ltd acquired a new stake in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter valued at about $12,660,000. Hedge funds and other institutional investors own 10.93% of the company’s stock.
ASLAN PHARMACEUTICALS ADR REP 5 Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.
Recommended Story: Preferred Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.